Stratec SE stock (DE000STRA555): Xetra trading focus ahead of 06/ 18/ 2026 AGM

Stratec SE shares on Xetra are trading in the high-20-euro range as investors look ahead to the 06/18/2026 general meeting in Germany, keeping attention on the diagnostics group’s positioning in the healthcare technology space.

Stratec SE shares on Xetra in Germany continue to change hands in the upper-20-euro range as investors position ahead of the company’s upcoming 2026 general meeting, maintaining focus on the diagnostics specialist’s standing in the SDAX segment of Deutsche Börse.

According to a recent overview, the stock traded at EUR 26.95 on Xetra on 06/02/2026, with the German listing active under ISIN DE000STRA555 and the instrument identified domestically under the STRA55/SBS designation, underscoring the company’s status as a Germany-listed healthcare technology name.

Germany remains the core home market for Stratec SE, with the primary listing on Xetra and inclusion among domestic small caps, where the company is tracked as part of the German SDAX universe for smaller issuers.

As of: 06/03/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Stratec
• Sector/industry: Medical technology and in-vitro diagnostics solutions
• Headquarters/country: Birkenfeld, Germany
• Core markets: Europe, North America, and other international diagnostics markets
• Key revenue drivers: Automated analyzer systems, OEM diagnostics platforms, and related consumables and services
• Home exchange/listing venue: Xetra (SBS)
• Trading currency: EUR

Stratec SE: core business model

Stratec SE develops and supplies automated analyzer platforms and integrated in-vitro diagnostics solutions to original equipment manufacturer customers, generating revenue primarily through system sales, long-term supply of consumables, and associated services.

Stratec SE in peer comparison

Within the medical technology and diagnostics space, Stratec SE competes with a range of European and international players that also focus on instrumentation and system solutions for laboratories and healthcare providers.

While some larger multinational groups address similar customer needs with broad portfolios across diagnostics and life sciences, Stratec SE is positioned more narrowly as an OEM-focused partner, emphasizing customized analyzer platforms and long-term supply relationships in contrast to more diversified peers that often market branded systems directly to end users.

Conclusion

With Stratec SE shares trading around EUR 26.95 on Xetra as of 06/02/2026 and the listing firmly anchored in Germany, the market’s attention is turning toward the June 2026 general meeting and any related corporate disclosures that may influence the diagnostics specialist’s trajectory.

In this context, the company’s role as an OEM partner in the in-vitro diagnostics ecosystem and its positioning among medical technology peers remain key reference points for investors evaluating the stock within the German small-cap healthcare segment.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.